Spectrum and Allos Announce FTC Clears Transaction of Allos Common Stock; Elan Announces Dosing of First Patient of ELND005 Print E-mail
By Staff and Wire Reports   
Wednesday, 29 August 2012 18:12
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 29, 2012.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
and Allos Therapeutics, Inc. (NasdaqGS: ALTH) announced the Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to the previously announced pending acquisition of all outstanding shares of common stock of Allos by Spectrum.

As previously disclosed, Spectrum has commenced a tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes.

Spectrum intends to accept for payment shares of Allos common stock validly tendered and not withdrawn prior to the scheduled tender offer expiration at 5:00 p.m., Eastern time, on Tuesday, September 4, 2012. The consummation of the tender offer is conditioned upon the tender of a majority of the outstanding shares of Allos common stock, as well as other conditions that are specified in the Schedule TO filed with the Securities and Exchange Commission on April 13, 2012.

This acquisition is a transformational step for Spectrum, building upon our desire to add value for our shareholders and increasing our ability to meet the needs of cancer patients, stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. Key to the acquisition is the diversification of our portfolio of marketed products by adding Allos FOLOTYN, which targets the same physicians as our ZEVALIN product.


=====


Elan Corporation, plc (NYSE: ELN)
announced it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes.

The first patient has been dosed in the study.



Also Wednesday:



Acorda Therapeutics, Inc. (Nasdaq: ACOR)
today announced that it will present at two upcoming conferences in September.

Aradigm Corporation (OTCBB:ARDM)
(the “Company”) today announced that Nancy E. Pecota, Aradigm’s Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 5, 2012 at 8:00 am Eastern time.

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
today announced that it will present at the Stifel Nicolaus Healthcare conference in Boston. Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer, will provide an overview of the Company’s business on Wednesday, September 5, 2012 at 4:25 p.m. (ET).

BioSpecifics Technologies Corp. (NASDAQ: BSTC)
, a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Thomas L. Wegman, President of BioSpecifics, will present at the Stifel Nicolaus Weisel Healthcare Conferences 2012 at 9:45 am EDT on Wednesday, September 5, 2012 in Boston, MA.

Clovis Oncology, Inc. (Nasdaq: CLVS)
today announced that Company management will participate in two investor conferences during the month of September.

CONMED Corporation (NASDAQ: CNMD)
announced today that its Board of Directors has declared a quarterly cash dividend of $0.15 per share, payable on October 5, 2012 to all shareholders of record as of September 14, 2012.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST)
today announced that company management will discuss Cubist’s business activities and financial outlook at investor conferences during September 2012.

DoMark International Inc. (OTCBB:DOMK)
(the "Company" or "DoMark"), through its wholly owned subsidiary, SolaWerks Inc., is preparing to release updated editions of its revolutionary SolaPad and SolaCase cover and solar charging systems that fit all versions of the Apple (NASDAQ:AAPL) iPad and iPhone. Based on overwhelming customer feedback, SolaWerks has refreshed its SolaPad and SolaCase with new features, including softer covers among other features to be announced.

Durata Therapeutics (NASDAQ: DRTX)
today announced that data from multiple studies of its investigational drug dalbavancin and of the outpatient management of acute bacterial skin and soft tissue infection (abSSTI) will be presented in five posters during the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

EasyMed Services Inc. (CNSX:EZM) (OTCBB:EMYSF) (MUN:EY6)
(www.EasyMedMobile.com) today announced that Comédie-Française has signed for a trial of the International Medical Passport for their permanent staff of actors and employees.

Galectin Therapeutics Inc. (NASDAQ: GALT)
, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Dr. Harold H. Shlevin as Chief Operating Officer.

Ingen Technologies, Inc. (PINKSHEETS: IGNT)
, an emerging medical device manufacturer with proprietary patented medical products for the growing $4 Billion respiratory markets, announced today that the company has followed through with its promise to secure a national distributor for the new Oxyview product line.

Lannett Company, Inc. (NYSE MKT: LCI)
, today announced that the company will release its fiscal 2012 fourth-quarter and full-year financial results on Thursday, September 6, 2012 after the market closes.

Life Technologies Corporation (NASDAQ: LIFE)
today announced it will present at UBS Global Life Sciences Conference on Wednesday, September 19 at 11:30 AM ET.

Medicago Inc. (TSX: MDG) (OTCQX: MDCGF)
, a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner, Executive Vice-President Operations, will be presenting at the 2012 Stifel Nicolaus Healthcare Conference.

OncoSec Medical Inc. (OTCBB: ONCS)
, a company developing its ImmunoPulse and NeoPulse therapies to treat solid tumor cancers, announced it will be presenting at the Rodman & Renshaw 2012 Annual Global Investment Conference in New York City.

Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the following upcoming investment conferences in September.

Orthofix International N.V., (NASDAQ:OFIX)
(the Company) announced today that it will participate in ThinkEquity’s 9th Annual Growth Conference on Thursday, September 13th at 9:00 AM Eastern Time at the Le Parker Meridien in New York, New York.

PAREXEL International Corporation (NASDAQ: PRXL)
announced today that it will be presenting at the Robert Baird Healthcare Conference in New York.

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO)
, a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended ended June 30, 2012.

POZEN Inc. (NASDAQ: POZN)
, a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg).

Protalex, Inc. (OTCBB: PRTX)
, a clinical stage biopharmaceutical company focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including rheumatoid arthritis (RA), today announced results from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA)
, a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that Dr. Paul Ashton, President and CEO, has been invited to participate as a distinguished speaker at the Drug Delivery Technologies & Formulation Conference taking place on September 5-6 in Zurich Switzerland.

Puma Biotechnology, Inc. (OTCBB: PBYI)
, a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 11:30 a.m. EDT on Wednesday, September 5, at the Stifel Nicolaus 2012 Healthcare Conference in Boston.

Repligen Corporation (NASDAQ:RGEN)
today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston.

Rockwell Medical (NASDAQ: RMTI)
, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that Robert L. Chioini, Chairman and CEO of Rockwell, along with Dr. Ajay Gupta, Chief Scientific Officer, will present at the 2012 Stifel Nicolaus Healthcare Conference taking place at the Four Seasons Hotel in Boston, Massachusetts on Wednesday, September 5, 2012 at 3:50pm ET.

Stevia First Corp. (OTCBB: STVF)
("Stevia First" or the "Company"), an early-stage agribusiness based in California's Central Valley growing region and focused on the industrial scale production of stevia, the all-natural zero-calorie sweetener that is rapidly transforming the food and beverage industry, is pleased to advise that the Company has entered into an exclusive and worldwide intellectual property license with the Vineland Research and Innovation Centre ("Vineland") of Ontario, Canada (www.vinelandresearch.com).

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)
today announced that the Company will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 9:10 a.m. (ET) in Boston.

Targacept, Inc. (NASDAQ: TRGT)
, a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Alan A. Musso, Senior Vice President, Finance and Administration and Chief Financial Officer, is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference at Four Seasons Hotel Boston on Wednesday, September 5, 2012 at 1:30 p.m. Eastern Time.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter